Ritlecitinib + Ritlecitinib 100 mg + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vitiligo
Conditions
Vitiligo
Trial Timeline
Jan 19, 2024 → Apr 23, 2027
NCT ID
NCT06163326About Ritlecitinib + Ritlecitinib 100 mg + Placebo
Ritlecitinib + Ritlecitinib 100 mg + Placebo is a phase 3 stage product being developed by Pfizer for Vitiligo. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06163326. Target conditions include Vitiligo.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06163326 | Phase 3 | Recruiting |
Competing Products
20 competing products in Vitiligo